Drug-resistant fungal infection rising in England

The UK Health Security Agency (UKHSA) has warned that a “previously rarely detected” fungus, Candidozyma, is rapidly spreading across England. The fungus can cause “silent colonization” or lead to severe and invasive infections. It is particularly concerning because it provokes outbreaks within hospitals and other healthcare facilities. The WHO has listed Candidozyma, also known as Candida C auris, as a fungal pathogen of critical priority due to its severity and drug resistance. Candida C auris can infect various body parts with symptoms mirroring bacterial infections or without showing any symptoms. This last condition is called “colonization” and allows the fungus to transfer to surfaces, objects, or other persons.
Candida C auris affects individuals with serious pre-existing health conditions and those who require invasive medical treatment. The devices used for such kind of treatment (breathing tubes, urinary catheters, feeding tubes) can provide entry points for the fungus into the body. Generally, healthy individuals do not contract the pathogen. Another key aspect is the resistance of Candida C auris to several antifungal treatments with drugs like fluconazole. This resistance can also be acquired by the pathogen during therapy.
There have been over 600 Candida C auris cases in England between 2013 and 2024, including both infections and colonizations. The bulk of them have been reported in the London region and the South-East. The UKHSA is working with NHS England and other partner organisations to respond to the increasing detection of the fungus in hospital settings.